All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Outpatient administration of CAR T-cell therapies in patients with hematological malignancies
Bookmark this article
|
A single-center retrospective analysis reported outcomes of outpatient administration of commercially available chimeric antigen receptor (CAR) T-cell therapies, using a strategy of no remote monitoring and early intervention for cytokine release syndrome (CRS).1 This analysis included 58 adult patients with hematological malignancies (multiple myeloma, 33; lymphoma, 24; acute lymphoblastic leukemia, 1) who received a commercial CAR T-cell therapy from January 2022 onwards. Results were published in Blood Advances by Furqan et al.1 |
| Key learnings |
|
In total, 72% of patients were admitted to the hospital in the first 30 days; 40% in Days 0–3, 38% in Days 4–7, and 22% in Days 8–30, with the most common reason for hospitalization being CAR T-cell-related toxicities. |
|
Early outpatient intervention using tocilizumab for Grade ≥1 CRS effectively reduced hospitalization rates, as demonstrated by the 15 out of 35 patients who received tocilizumab for CRSavoiding admission. |
|
The analysis reported a low rate of non-relapse mortality (1.7% at 1 month and 3.4% at 6 months in patients with lymphoma; 0% at 1 and 6 months in patients with multiple myeloma), suggesting that this strategy does not compromise patient safety. |
|
The results suggest that implementing CAR T-cell administration in an outpatient setting is safe and feasible without intensive remote monitoring using an early CRS intervention strategy and may lead to reduced healthcare resource utilization and improved patient quality of life by minimizing hospital admissions.
|
- Furqan F, Bhatlapenumarthi V, Dhakal B, et al. Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention. Blood Adv. 2024;8(16):4320-4329. DOI: 1182/bloodadvances.2024013239
More about...
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox